Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma. Review uri icon

Overview

abstract

  • The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.

publication date

  • January 1, 2016

Research

keywords

  • Antineoplastic Agents
  • Hodgkin Disease
  • Immunoconjugates
  • Ki-1 Antigen
  • Molecular Targeted Therapy

Identity

PubMed Central ID

  • PMC5042201

Scopus Document Identifier

  • 84957688772

Digital Object Identifier (DOI)

  • 10.1097/PPO.0000000000000168

PubMed ID

  • 26841013

Additional Document Info

volume

  • 22

issue

  • 1